MetaVia reports results from Phase 1b trial of DA-1726

MetaVia (MTVA) announced positive statistically significant results from the 8-week non-titrated 48 mg, multiple ascending dose cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin, OXM, analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor, for the treatment of obesity. The results show robust early weight loss, statistically significant reductions in waist circumference, strong improvements in glucose control, and meaningful reductions in liver stiffness, alongside a favorable safety and tolerability profile. In the non-titrated 48 mg cohort, patients experienced no treatment-related discontinuations, and gastrointestinal events were mild to moderate in severity. By Day 26, patients receiving DA-1726 achieved a statistically significant average weight reduction of 6.1% and a statistically significant decrease in waist circumference of 5.8 cm. These improvements deepened through Day 54, with an average weight loss of 9.1% and a statistically significant 9.8 cm reduction in waist circumference. Patients also demonstrated a 12.3 mg/dL improvement in fasted glucose from a baseline of 105.3 mg/dL by Day 54. In addition, vibration-controlled transient elastography indicated a 23.7% reduction in liver stiffness from a baseline of 5.9 kPa, suggesting a significant direct hepatic effect from DA-1726.